Science Explorer Interactive view Map
Company · Leeds · United Kingdom

Avacta (United Kingdom)

Research works
22
▲ 120% vs 2013–17
Citations
216
9.7 per fractional work
Top-10% rate
4.3%
record average 16.5%
Open access
42%
world 28%

Not ranked overall: Avacta (United Kingdom) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which keywords describe research at Avacta (United Kingdom)?

By fractional works in all years, weighted toward what it does more of than the world: Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Cancer Therapy, Immunotherapy and Gene Therapy.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 26 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 26 words, with their numbers
  1. Glycosylation4▲ 78×2 topics
  2. Monoclonal Antibodies3▲ 102×2 topics
  3. Therapeutic Antibodies3▲ 114×2 topics
  4. Antibody Engineering3▲ 132×1 topic
  5. Fc Receptors3▲ 132×1 topic
  6. Cancer Therapy2▲ 17×6 topics
  7. Immunotherapy2▲ 14×6 topics
  8. Gene Therapy2▲ 34×2 topics
  9. Nanoparticles2▲ 5.3×4 topics
  10. Angiogenesis1▲ 16×5 topics
  11. RNA Interference1▲ 55×1 topic
  12. siRNA Delivery1▲ 81×1 topic
  13. Tumor Regression1▲ 68×2 topics
  14. Biosensors1▲ 9.6×2 topics
  15. Cancer1▲ 3.9×3 topics
  16. Epidemiology1▲ 1.32×2 topics
  17. Molecular Machines1▲ 44×2 topics
  18. PET Imaging1▲ 24×2 topics
  19. Self-Assembly1▲ 13×2 topics
  20. DNA nanotechnology1▲ 50×1 topic
  21. Proteasome1▲ 118×1 topic
  22. Ubiquitin1▲ 118×1 topic
  23. aptamers1▲ 50×1 topic
  24. Antigen Presentation1▲ 45×2 topics
  25. Cancer Immunotherapy1▲ 32×2 topics
  26. Tumor Targeting1▲ 35×3 topics

Which research topics does Avacta (United Kingdom) publish most on?

By volume in 2022–2025: RNA Interference and Gene Delivery, Radiopharmaceutical Chemistry and Applications, Peptidase Inhibition and Analysis and Nanoplatforms for cancer theranostics.

  1. 1 RNA Interference and Gene Delivery Molecular Biology 1 works
  2. 2 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
  3. 3 Peptidase Inhibition and Analysis Oncology 0 works
  4. 4 Nanoplatforms for cancer theranostics Biomedical Engineering 0 works
  5. 5 Advanced biosensing and bioanalysis techniques Molecular Biology 0 works
  6. 6 Cell Adhesion Molecules Research Immunology and Allergy 0 works
  7. 7 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  8. 8 Supramolecular Chemistry and Complexes Organic Chemistry 0 works
  9. 9 Connective tissue disorders research Genetics 0 works
  10. 10 Neuroendocrine Tumor Research Advances Epidemiology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available41.5%not open58.5%

World: 28% of research is openly available.

with international co-authors20.9%domestic only79.1%

World: 19% is written across borders.

How has Avacta (United Kingdom)'s research output changed?

Output in 2018–2022 was 120% higher than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Leeds

All research institutions in Leeds

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.